OraSure Appoints Anne Messing as Chief Commercial Officer
Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliances, and Product Management, and will shape the vision and management of OTI's product portfolio in its aim to achieve market leadership and drive long-term growth.
Prior to joining OTI, Ms. Messing was Vice President and General Manager of the U.S. Region for Becton Dickinson (BD) Biosciences, spearheading initiatives that outperformed market benchmarks and generated meaningful sales growth from legacy products as well as new product launches. Complementing her 12 years of sales and marketing leadership at BD, she also has deep healthcare experience from prior roles at Danaher, Quest Diagnostics, Siemens Healthcare Diagnostics, and ARUP Laboratories. She spent the early part of her career in the lab as a certified medical technologist and advanced through various levels of management to ultimately lead all the clinical laboratories at Beaumont Hospital in Royal Oak, Michigan. She received her Bachelor of Science in Medical Technology from Northern Michigan University and her Master of Science in Administration from Central Michigan University.
'We are delighted to welcome Anne as our Chief Commercial Officer. I am confident that her deep expertise, motivational leadership, and proven success in delivering results will create exceptional value for our internal and external stakeholders,' said Carrie Eglinton Manner, President and CEO of OTI. 'Leveraging her strengths, she will be instrumental in driving the organization forward as we continue to execute our mission to improve access, quality, and value in healthcare through innovative solutions in effortless testing and sample management.'
'I'm excited to step into this transformative chapter with OTI, as the company accelerates its vision for the future and prepares for a wave of impactful and strategic product launches,' Messing said.
About OraSure Technologies
OraSure Technologies, Inc. ('OraSure' and 'OTI') transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com.
Forward Looking Statements
This press release contains certain 'forward-looking statements.' Forward-looking statements are based on current expectations of future events and are not guarantees of future performance or results. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: uncertainty of commercial success; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; uncertainty of regulatory approvals; ability to comply with applicable regulatory requirements; uncertainty relating to patent protection and potential patent infringement claims; impact of competitors, competing products and technology changes and patents obtained by competitors; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; impact of negative economic conditions; changes in behavior and spending patterns of purchasers; trends toward healthcare cost containment; product efficacy or safety concerns resulting in product recalls or regulatory action; and changes to applicable laws and regulations. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
Investor Contact:
Media Contact:
Jason Plagman
Amy Koch
Vice President, Investor Relations
Director, Corporate Communications
investorinfo@orasure.com
media@orasure.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
elf Beauty (ELF) Jumps 9.7% as Analyst Grows More Bullish Despite Product Price Increase
We recently published . e.l.f. Beauty, Inc. (NYSE:ELF) is one of the best-performing stocks on Monday. e.l.f Beauty saw its share prices jump by 9.73 percent on Monday to finish at $111.67 apiece as investors took heart from an investment firm's bullish rating and price target upgrade for its stock. In a market note, Morgan Stanley upgraded e.l.f. Beauty, Inc. (NYSE:ELF) to 'overweight' from 'equal weight' previously, alongside a higher price target of $134 versus $114 prior. The new price suggested a 20-percent upside potential from its latest closing price. Last August 1, e.l.f. Beauty, Inc. (NYSE:ELF) slapped a 14-percent price hike on its products, saying that it would assess how consumers would respond. 'It will take a couple of weeks for that to fully roll out within retail. And so that is something that we're watching for,' e.l.f. Beauty, Inc. (NYSE:ELF) CFO Mandy Fields has said. However, Morgan Stanley posted a more optimistic outlook, saying that consumers typically do not tend to be especially sensitive to price increases 'given the relative importance of beauty products to consumers.' Copyright: citalliance / 123RF Stock Photo Additionally, it underscored that e.l.f. Beauty, Inc.'s (NYSE:ELF) products are relatively cheaper compared with those from its counterparts, and there is less opportunity for consumers to find more affordable substitutes. While we acknowledge the potential of ELF as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
9 minutes ago
- Yahoo
If You'd Invested $10,000 in Navitas Semiconductor Stock 2 Years Ago, Here's How Much You'd Have Today
Key Points Its partnership with Nvidia is proof of the long-term potential for silicon carbide and gallium nitride chips. Investors are looking to 2027 and the launch of new data centers to spur Navitas' growth. 10 stocks we like better than Navitas Semiconductor › If you're wondering how much you'd have if you'd invested $10,000 in Navitas Semiconductor (NASDAQ: NVTS) stock two years ago -- and I'm sure you are since you're reading this -- the answer is about $7,500 as I write this on Aug. 10. While that might surprise investors in Navitas Semiconductor who've only been watching it in 2025, as it's up 85% so far this year, it does highlight some points about investing in growth stocks. Why Navitas Semiconductor's stock has gone up so much in 2025 The simple reason for this year's jump comes down to the mid-May announcement of a partnership with Nvidia to develop data center power architecture for the next generation of data centers, due to launch in 2027. The new more efficient, reliable, and lower-maintenance cost 800 V data centers need silicon carbide (SiC) and gallium nitride (GaN) chips (Navitas' specialty) in the power conversion process in the new data centers. Considerations for growth investors The fact that the stock is down over the last couple of years indicates that patience is key when investing in growth stocks, and it pays to avoid getting caught up in euphoria. For example, in the summer of 2023, Navitas offered 11.5 million shares at a price of $8, which the market eagerly took up. Unfortunately, some of its key end markets, like electric vehicles and consumer electronics (notably mobile phones), slowed markedly, and the stock declined. However, it makes sense to buy into weakness if you have data-backed belief in the long-term growth prospects of a company. This has happened as investors have jumped back into Navitas on the Nvidia news. Do the experts think Navitas Semiconductor is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Navitas Semiconductor make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,060% vs. just 182% for the S&P — that is beating the market by 877.59%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. If You'd Invested $10,000 in Navitas Semiconductor Stock 2 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Fed's policy rate should stay on hold for now, Schmid says
(Reuters) -The U.S. central bank should not take tariffs' muted effect on inflation so far as an opportunity to cut interest rates, but rather as a sign that monetary policy is "appropriately calibrated," Kansas City Federal Reserve President Jeffrey Schmid said on Tuesday, in remarks that contrast with the increasingly dovish tone of some of his colleagues. "With the economy still showing momentum, growing business optimism, and inflation still stuck above our objective, retaining a modestly restrictive monetary policy stance remains appropriate for the time being," Schmid said in remarks prepared for delivery to an economic development conference in Oklahoma. "While increased tariffs seem to be having a limited effect on inflation, I view this as a rationale for keeping policy on hold rather than an opportunity to ease the stance of policy." Schmid said his "patient approach" to changing the policy rate, currently in the 4.25%-4.50% range, shouldn't be seen as a "wait and see" approach because he does not think that it will be clear in the next few months whether tariffs are pushing up on prices temporarily or persistently. Rather, he said, he feels the current policy rate is not very far above the neutral rate, where activity is neither stimulated nor restrained, and the labor market is still looking solid despite a sharp drop in job growth in recent months. And while the cooling labor market is keeping a lid on the pass-through of tariffs into inflation, boosting demand aggressively could raise the risk of an outsized increase in price pressures, Schmid said. "In my view, and in discussion with my contacts, growth remains solid, inflation remains too high, and therefore policy should remain modestly restrictive," he said. "That said, as I stated earlier, inflation is determined by the balance of supply and demand, and if I see indications that demand growth isweakening significantly, I will adjust my views accordingly." 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
